Gilenya (jill-LEN-nee-ya, fingolimod) is the first ORAL drug to reduce relapses in relapsing multiple sclerosis (MS)
November 2010
Please see the May 2012 FDA safety communication concerning Gilenya
Gilenya (jill-LEN-nee-ya, fingolimod) is the first ORAL drug to reduce relapses in relapsing multiple sclerosis (MS).It's a new immune modulator that prevents some white blood cells from migrating to the CNS and damaging it.
Gilenya is approved for first-line use...but don't expect it to replace beta-interferons (Avonex, etc) or Copaxone (glatiramer). These drugs have a longer safety record and they're less expensive.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote